Get the Stockscreener App
1.90
0.00%
0.00
Fractyl Health Inc stock is traded at $1.90, with a volume of 147.72K.
It is up +0.00% in the last 24 hours and up +20.25% over the past month.
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
See More
Previous Close:
$1.90
Open:
$1.91
24h Volume:
147.72K
Relative Volume:
0.61
Market Cap:
$93.06M
Revenue:
-
Net Income/Loss:
$-56.85M
P/E Ratio:
-1.2187
EPS:
-1.559
Net Cash Flow:
-
1W Performance:
+5.56%
1M Performance:
+20.25%
6M Performance:
-26.64%
1Y Performance:
-71.81%
1-Day Range:
$1.86
$1.95
1-Week Range:
$1.77
$2.0374
52-Week Range:
$0.873
$7.05
Fractyl Health Inc Stock (GUTS) Company Profile
Name
Fractyl Health Inc
Sector
Industry
Phone
781-902-8800
Address
3 VAN DE GRAAFF DRIVE, BURLINGTON
Compare GUTS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GUTS
Fractyl Health Inc
|
1.90 | 95.50M | 0 | -56.85M | 0 | -1.559 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Fractyl Health Inc Stock (GUTS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-28-24 | Initiated | Evercore ISI | Outperform |
| Feb-27-24 | Initiated | BofA Securities | Buy |
| Feb-27-24 | Initiated | Morgan Stanley | Overweight |
Fractyl Health Inc Stock (GUTS) Latest News
Northern Trust Corp Sells 9,467 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Fractyl Health, Inc. (NASDAQ:GUTS) Shares Sold by Citadel Advisors LLC - Defense World
Transcript : Fractyl Health, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 05 - marketscreener.com
Fractyl Health submits first module of its CTA in Europe for RJVA-001 - TipRanks
Fractyl Health advances gene therapy for diabetes treatment By Investing.com - Investing.com South Africa
Fractyl Health advances gene therapy for diabetes treatment - Investing.com Australia
Fractyl Health Submits Clinical Trial Application in Europe - TipRanks
Fractyl Health Submits First Module of EU Trial Application for Gene Therapy RJVA-001 - marketscreener.com
Fractyl Health Unveils Promising Gene Therapy Data - TipRanks
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial ... - Eagle-Tribune
Fractyl Health Advances Rejuva® Gene Therapy Platform with - GlobeNewswire
Breakthrough One-Time Gene Therapy Could Replace Daily Diabetes Drugs, Heads to European Trials - Stock Titan
China On the March as U.S. Investors Plough Back in After Tariff Tension - The Globe and Mail
Fractyl Health Announces Promising Preclinical Data for RJVA-001, a Novel Gene Therapy for Type 2 Diabetes at ASGCT 2025 - Nasdaq
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data ... - Eagle-Tribune
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic - GlobeNewswire
Revolutionary One-Time GLP-1 Gene Therapy Achieves Powerful Diabetes Control with 5X Lower Side Effect Risk - Stock Titan
Prediction: Taiwan Semiconductor Stock Could Surge by 129% in the Next 5 Years - The Globe and Mail
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise - The Globe and Mail
Analysts and Institutions Continue to Bet Big on Alphabet - The Globe and Mail
16,400 Shares in Fractyl Health, Inc. (NASDAQ:GUTS) Bought by Raymond James Financial Inc. - Defense World
Fractyl signals accelerated enrollment for REMAIN-1 study while advancing Rejuva clinical milestones - MSN
Forge Biologics Inks AAV Development and cGMP Manufacturing Deal with Fractyl Health - Genetic Engineering and Biotechnology News
Fractyl Health Partners with Forge for Rejuva Gene Therapy Development - Contract Pharma
Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases - Business Wire
1 Super Stock Down 76% You'll Regret Not Buying on the Dip in 2025 - The Globe and Mail
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates - GlobeNewswire
Fractyl Health Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Fractyl Health’s Q1 2025 shows rising R&D costs - Investing.com Nigeria
FRACTYL HEALTH, INC. SEC 10-Q Report - TradingView
Should You Buy Roku Stock Now With $500 and Hold for 10 Years? - The Globe and Mail
These High-Growth Stocks Were Down Over 50% This Year. Is It Time to Buy Them? - The Globe and Mail
Fractyl Health (GUTS) Expected to Announce Earnings on Tuesday - Defense World
Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference - The Manila Times
Fractyl Health to Report First Quarter 2025 Financial - GlobeNewswire
Fractyl Health Sets Date for Q1 Earnings, Showcases Diabetes Therapeutics at Major Healthcare Conference - Stock Titan
Geode Capital Management LLC Purchases 11,603 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Fractyl Health, Inc. to Present Preclinical Data on Rejuva Gene Therapy Platform at ASGCT 2025 Annual Meeting - Nasdaq
Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting - The Manila Times
Fractyl Health to Present Compelling Preclinical Data from - GlobeNewswire
Discover Fractyl Health And 2 More Promising Penny Stocks - Yahoo Finance
Fractyl Health (NASDAQ:GUTS) Earns Buy Rating from Analysts at Canaccord Genuity Group - Defense World
These Were the 2 Worst-Performing Stocks in the S&P 500 in March 2025 - The Globe and Mail
Fractyl Health initiated with a Buy at Canaccord - TipRanks
Meta Stock Holds Its Head Up High amid Full-Blown Legal Migraine - The Globe and Mail
Raymond James Financial Inc. Makes New Investment in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Sei Investments Co. Acquires Shares of 27,778 Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Norges Bank Makes New Investment in Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Critical Analysis: Glaukos (NYSE:GKOS) & Fractyl Health (NASDAQ:GUTS) - Defense World
NeuroMetrix (NASDAQ:NURO) vs. Fractyl Health (NASDAQ:GUTS) Head-To-Head Survey - Defense World
HighTower Advisors LLC Acquires 10,921 Shares of Fractyl Health, Inc. (NASDAQ:GUTS) - Defense World
Fractyl Health Inc Stock (GUTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):